Background <p>Parkinson’s disease (PD) is a complex, progressive neurodegenerative disorder with patients experiencing an increased number and severity of motor and non-motor symptoms over the course of their disease. Despite the exponentially increasing prevalence of PD worldwide, therapies for people with PD remain symptomatic in nature.</p> Purpose of Review <p>This review provides an update on the advances in the pharmacological management of both motor and non-motor symptoms in people with PD.</p> Recent Findings <p>It highlights several newly approved pharmacological options for ON/OFF motor fluctuations and levodopa-induced dyskinesia. This review details the novel device-aided therapies of intravenous levodopa/ carbidopa along with the unique delivery systems approved for PD rescue therapy. This review concludes with an update on the recent progress made in the treatment of a number of non-motor symptoms.</p> Conclusion <p>Although disease-modifying and neurorestorative therapies remain the Holy Grail in PD, the current advances in symptomatic pharmacological therapies are welcomed in the armamentarium of PD care.</p>